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Old age is a risk factor for cancer development in humans and animals, and studies have 
shown that tumors in animals are acceptable models for studying human cancers, considering the 
similarities between their factors. This work was conducted in a 53-year-old captive female common 
hippo (Hippopotamus amphibious) with a left leg tumor and metastatic mass. Histopathological and 
immunohistochemical analyses were carried out with a final diagnosis of a high grade pleomorphic 
sarcoma. A proteomic study using mass spectrometry was added in order to identify further aspects 
of the primary tumor and metastasis which could improve our understanding, and each tissue showed 
a proteomic profile indicative of its pathologic state with significant differences between healthy 
tissue, primary and metastatic tumors. Low levels of β-actin in primary tumors were identified, 
and this may be associated with a possible consequence of cytoskeleton dynamic modification. In 
metastatic tissue, these dynamics may be affected by the presence of HSP chaperone 60.
Keywords: Hippopotamus amphibious, high grade pleomorphic sarcoma, cytoskeleton, 
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Introduction
Oncogenic phenomena in animals include a wide 
variety of benign and malignant tumors that develop during 
the life of the animal and have several health consequences.1 
Species with large bodies tend to have a lower cancer rate, 
which seems to indicate the presence of complex tumor 
detection systems (Peto’s paradox).2 To illustrate this 
paradox, in contrast with humans, who have only two copies 
of the TP53 tumor suppressor gene, elephants, the largest 
of the land mammmals, have 20 copies of the TP53 gene. 
This allows for extra efficiency in their systems, enabling 
the correction of DNA damage or inducing apoptosis in 
mutated cells. As a result, only 3% of elephants develop 
cancer.3,4
Despite some comparative cancer and lifespan analyses 
between wild and zoo animals showing that captive animals 
were susceptible to cancer and decreased longevity.5,6 
Tidière et al.7 revealed that mammals from zoo populations 
generally lived longer than their wild counterparts (84% of 
species). Of particular interest, the common hippopotamus 
(Hippopotamus amphibius), a robust mammal with an 
estimated 40-year lifespan in nature and with slow pace of 
life, has increased longevity in captivity.7-9 The relationship 
between life expectancy and environment may be associated 
with the low caloric diet and reduced metabolism present 
in captive animals, which slows ageing and the appearance 
of cancer cases. This is also true for humans.10,11
Paradoxically, the exceptional longevity these captive 
animals exhibit can be associated with cancer due to several 
factors such as telomere shortening, increased cellular 
senescence, accumulation mutation of DNA in stem and 
progenitor cells required for active replenishment during 
the lifespan of the organism, mutations in tumor suppressor 
genes and metabolic changes.12-14
Based on available database information and proteomics 
approach, it is possible to differentiate proteomes in healthy 
and pathological conditions to obtain an understanding of 
cancer at the molecular level for the purpose of describing 
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molecular processes and identification of biomarkers.15,16 
Thus, the objective of this study was to differentiate 
the proteomes of healthy skeletal muscle, high grade 
pleomorphic sarcoma and heart metastasis diagnosed in 
a common hippo, located at a zoo, with high longevity, 
and to identify possible biomarkers responsible for the 
development and progression of these conditions.
Experimental
Animal aspects and samples collection
The animal under examination was a female common 
hippo (Hippopotamus amphibious) aged 53 years 
presenting with prolonged anorexia and weight loss. 
Clinical and radiological examinations of the posterior and 
upper limbs revealed severe bone disease and osteoarthritis 
of both metacarpophalangeal joints. During autopsy, 
a 27 cm pink to gray main tumor mass attached to the 
left tibial crest near the cranial epiphysis was detected. 
There were also several white to gray nodules in the lungs 
(2 to 5 cm), heart (0.5 to 1.0 cm), mesenteric lymph nodes 
(1.5 cm) and liver (12 cm). Tissue samples were collected 
from a primary tumor present in the paw, healthy skeletal 
muscle around the tumor, and metastatic tissue from heart. 
All the samples remained at −80 °C until the time of the test.
Histopathological and immunohistochemical analysis
Samples were fixed in 10% neutral buffered formalin, 
embedded in paraffin, sectioned at 4 µm, and stained with 
hematoxylin and eosin (H&E). Immunohistochemistry was 
also performed on tumor sections according to a previously 
described protocol.17 Based on histological findings, primary 
antibodies were used to detect antigens from mesenchymal 
tissues with Vimentin (V9), muscle with Desmin (D33) and 
α-SMA (1A4), histiocytes with CD 34 (QBEnd 10), CD45 
(2B11-PD7/26) (DakoCytomation, Glostrup, Denmark) 
and Lysozyme (polyclonal), neuroendocrine tissues with 
S100 (polyclonal) and epithelial tissues with cytokeratin 
cocktail (AE1AE3), and EMA (E29). All antibodies used 
were from DakoCytomation, Denmark. Normal tissues 
from the hippopotamus were used as negative and positive 
controls for the reactions.
Sample preparation for proteomic analysis
Samples (500 mg) were ground in liquid nitrogen, 
homogenized and solubilized in 500 µL of lysis buffer 
(25 mmol L−1 Tris base pH 8.5, 1% Triton X, 4% CHAPS, 
1 mmol L−1 phenylmethylsulfonyl fluoride) with 750 µL 
of protease inhibitor (Roche, Basel, Switzerland). The 
homogenate was centrifuged at 5000 rpm at 4 °C for 10 min 
with 125 µL of trichloroacetic acid containing 80 mmol L−1 
dithiothreitol (DTT). The supernatant was discarded, and 
the precipitate was washed with 500 µL of ice-cold acetone 
containing 20 mmol L−1 DTT and centrifuged at 13,000 rpm 
at 4 °C for 10 min; the washing and centrifugation steps 
were repeated 3 times. The supernatant was discarded and 
the precipitate was dried by evaporation and resuspended in 
extraction buffer (40 mmol L−1 Tris base pH 8.5 containing 
7 mol L−1 urea, 2 mol L−1 thiourea, 4% CHAPS and 
65 mmol L−1 DTT), and solubilized at 300 rpm overnight 
at 4 °C. The sample was centrifuged at 13,000 rpm at 4 °C 
for 10 min, and detergent was removed from the supernatant 
with Pierce Detergent Removal Spin Columns (Thermo 
Fisher Scientific Inc., USA) according to the manufacturer’s 
recommendations. Total protein was determined using the 
Bradford method.18
Proteins were reduced with 5 mmol L−1 DTT for 30 min 
at 56 °C, then alkylated with 14 mmol L−1 iodoacetamide 
for 30 min in the dark. Proteins were further reduced with 
5 mmol L−1 DTT for 30 min at 56 °C, with the addition of 
50 mmol L−1 NH4HCO3 plus CaCl2 1 mmol L−1 (100 µL) for 
pH adjustment and reduction of self-enzymatic proteolysis. 
The chemicals used were purchased from Sigma-Aldrich, 
USA. The samples were subjected to enzymatic digestion 
overnight at 37 °C with trypsin 1:50 (m/m) (sequencing-
grade modified trypsin, Promega, USA), and the reaction 
was quenched with the addition of 0.1% trifluoroacetic 
acid (TFA).
Nano high performance liquid chromatography tandem 
mass spectrometry (HPLC-MS/MS) analysis
The solutions containing the eluted peptides were 
concentrated in a SpeedVac at 20 °C and resuspended in 2% 
acetonitrile + 0.1% formic acid. Concentrates were injected 
into ultra-high performance liquid chromatography systems 
(UHPLC) Nano-Advance (Bruker Daltonics, Germany) 
in a reverse phase C18 column 150 × 0.1 mm at a flow of 
0.1 mL min−1 and injection volume of 5 µL. Formic acid 
gradients consisted of 0.1% formic acid in water (solvent 
A) and 0.1% formic acid in acetonitrile 95% (solvent B), 
with an initial concentration of 2% solvent B and a gradual 
increase to 10-90% solvent B over 120 min. The MS data 
was acquired with a micrOTOF QII mass spectrometer 
(Bruker Daltonics, Germany). The acquisitions were made 
in the range of m/z 200-1500, with the following parameters: 
quadrupole ion energy 6.0 eV; collision energy 12 eV s−1; 
radio frequency (RF) collision 600 Vpp; 140 µs time transfer; 
and pre-pulse 14 µs storage. The time-of-flight repetition 
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rate was 5.0 kHz frequency 2 GHz with flight tube 8600 V, 
reflector 1700 V, 1700 V detector source, TOF 2140 V 
detector and collision energy 8 keV. The MS/MS spectra 
were obtained by collision-induced dissociation (CID).
Bioinformatics analysis
The MS/MS spectra were analyzed using Peaks Studio 
7.0 software (Bioinformatics Solutions, Waterloo, Canada) 
for de novo analysis and multi-round database search.19 
Based on the low number of proteins available in the 
hippopotamus database, the de novo sequenced peptides 
with average local confidence (ALC) scores ≥ 50% were 
selected for database searches against Mammalian databases 
from UniProt20 in the first round and NCBI21 in the second 
round. The MS/MS spectra were carried out with precursor 
mass tolerance of 10 ppm, fragment mass tolerance of 
0.5 Da, trypsin as specific-enzyme, with up to 02 missed 
cleavages and 01 non-specific, carbamidomethylation 
on cysteine (+57.02) as fixed modification, oxidation on 
methionine (+15.99 Da) as the variable modification and 
false discovered rate (FDR) < 5%.
Peptides with length of amino acids ≥ 6 and ALC ≥ 65% 
obtained by de novo analysis not matching any sequence in 
the database searches were submitted to homology search 
in BLAST analysis22 using the sequence presets against the 
UniprotKB (Mammalian) database and hits E-values < 2 
was used as the limit parameter.
PANTHER analysis was used to classify protein 
function23 in healthy, tumor and metastasis tissues based 
on Gene Ontology (GO) terms. The percentage values were 
therefore normalized to a total value of 100%.
Results and Discussion
High grade pleomorphic sarcoma diagnosed by the morpho-
immunological aspects
The tumor was composed of plump spindle cells 
forming fascicular and storiform patterns, with admixed 
bizarre pleomorphic and multinucleated giant cells on a 
background of mononuclear inflammatory cells. There were 
an average of three mitotic figures per 10 high power fields 
and bizarre mitoses were common. The cystic, gritty areas 
seen grossly proved to be foci of myxoid degeneration, 
necrosis and mineralization. The tumor was high positive 
for vimentin, had patchy SMA staining and was negative for 
all other markers, consistent with a high grade pleomorphic 
sarcoma, not otherwise specified (Figure 1).
Many of these tumors showed focal immunoreactivity for 
smooth muscle actin, but stains for desmin and h-caldesmon 
are typically negative.24 The high grade undifferentiated 
pleomorphic sarcoma (UPS) manifests in a broad range 
of histologic appearances, although the most common 
form consists of a mixture of storiform and pleomorphic 
areas, and it is diagnosed when no identifiable specific 
line of differentiation exists, excluding dedifferentiated 
types of pleomorphic sarcomas (diagnosis of exclusion). 
Overall, the morphologic and immunohistochemical results 
described are consistent with a conclusive diagnosis of this 
tumor type.25
Protein profiling describes differences in pathological status 
between tissues
Currently, little information about the proteome of 
common hippos exists, but MS/MS analysis enables the 
observation of the proteomic changes in the different tissues, 
which can be compared to differentiate the physiopathological 
status among them. Of the proteins identified, 25 were found 
in healthy skeletal muscle, 27 in primary tumors, and 15 in 
metastatic tumors (Supplementary Information); uncommon 
characteristics were shown between normal and tumor 
tissues based on protein class annotated in GO terms. These 
differences were observed mainly by the number of proteins 
associated to the cytoskeleton, in healthy tissue (36.7%), 
which decreased in the pathological tissues. Meanwhile, 
proteins identified in primary and metastasis tumors revealed 
enrichment for nucleic acid binding, which is absent in 
normal tissue (Figure 2).
The nucleic acid binding PANTHER protein class 
includes RNA and DNA binding proteins, helicases and 
nucleases. The abundance of these proteins differentially 
encoded in malignant samples may suggest altered 
transcriptional activity in tumor samples.26 Evidence 
suggests that activated nucleic acid binding proteins might 
play a vital role in cell growth, abnormal cell proliferation, 
and metastasis, and may form a network center during 
carcinogenesis.27
Thus, when comparing diseased and control tissues, it 
is relevant to consider the amount associated with the GO 
category as well as the number and function of the proteins. 
The normal muscle sample was characterized by structural 
proteins related to contractile muscle function, the formation 
of microtubules, and the composition/maintenance of the 
cytoskeleton, with effects on cell division. These proteins 
included actin, myosin, tropomyosin, titin, filamin, dynein, 
receiver skeletal protein tyrosine kinase, protein kinase 
PAK 3, microtubule-associated protein ASPM (abnormal 
spindle microtubule) and various isoforms.28-31 The presence 
of these proteins seems to indicate there was no stress at 
the cellular level.
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The primary tumor had proteins in common with healthy 
tissue, but with a peculiar proteome. Proteins associated 
with DNA damage were detected along with a possible 
mutation in a protein commonly found in healthy tissue, 
which may elucidate the cellular mechanism of the protein. 
Excess soluble histone proteins is an indicative of damage 
to the nucleosome, which impacts DNA replication and 
may negatively affect the repair of the DNA molecule.32,33 
An increase in protein synthesis by the methionyl-tRNA 
synthetase enzyme is also related to oncogenesis,34 as is 
an increase in the transcription factor that binds the EFL 1 
promoter, responsible for increasing transcription in tumors 
and during angiogenesis.35,36
Some proteins that act to restore homeostasis were also 
detected, including the DNA repair protein PMS237 and 
CTCF tumor suppressor,38 as well as proteins involved in 
stress response, including the small chaperone crystalline 
alpha39 and the chaperone HSP 60.40 The presence of 
vimentin was detected; this protein was associated with the 
cytoskeleton in tumor cells and is responsible for increasing 
adhesion and metastasis, but it is poorly expressed during 
myogenesis in normal cells.41,42 The different intracellular 
dynamics and tissue organization in tumors could also be 
observed in changes in the levels of TMPRSS matriptase, 
which increases collagen degradation and the effects of 
iron exposure.43,44
Figure 1. Comparative photomicroscopy of the histological differences between tissues show progression and differentiation of tumor from skeletal muscle 
and aspects of heart metastasis. (a) Skeletal muscle tissue; (b) transition of skeletal muscle to tumor tissue; (c, d) tumor tissue; (e, f) heart metastatic tissue. 
Hematoxylin and eosin (H & E).
Silva et al. 367Vol. 29, No. 2, 2018
of tumors which do not require anchoring.46 The initiator of 
transcription factor 2 alpha (GCN2) is a protein expressed 
in the absence of nutrients. It is related to various pathways 
of tumor progression and angiogenesis47,48 and increases 
fibroblast growth factor.49
The efrin A2 receptor is associated with oncogenesis 
and with the progression of metastatic growth factors, 
such as fibroblast growth factor.50 Proteins involved in 
cell proliferation were also found, including GSG2, a 
kinase responsible for mitotic histone production51 and 
guanine nucleotide exchange factor RASGRF1, which is 
responsible for cell proliferation and migration related to 
metastatic in tumorogenesis.52 However, this tissue also 
showed the presence of tumor suppressor CHD1.53
Decreased level β-actin in primary tumor in response to 
possible cytoskeleton dynamic modification
De novo sequenced peptides used to identify proteins 
had MS/MS spectra manually verified. Based in the 
retention time (RT), m/z ratio of precursor ion, and sequence 
coverage, we identified peptides of β-actin protein that 
were present in all tissues. Based on the extension to 
the spectral counting technique by the average of the 
total ion current (TIC) of MS/MS spectra this peptides, 
it was estimated their relative abundance of the protein, 
similarly to a label-free quantification.54
Despite similarities among malignant samples, the 
β-actin present in primary tumors showed minor abundance 
compared with the other tissues, but there was no significant 
difference between healthy and metastatic tissues. Some 
differences in sequence coverage may be considered 
tolerable error-fragmentation, i.e., AG → K55 (Figure 3).
Based on both literature reports and the proteomic 
profile of the primary tumor generated, we suggest that 
the reduction of β-actin (actin cytoplasmic 1) is the result 
of the progressive increase of the cytoskeleton through a 
dynamic process involving changes in its dynamics, and 
for the presence of protein connections that bind to this 
structure with subsequent alteration of gene expression in 
the tumor. The presence of vimentin and crystalline alpha 
proteins increases stability of the cytoskeleton by reducing 
depolymerization.56,57
The results of decreased depolymerization is an 
increase of the cytoskeleton with membrane protrusion, 
tumor progression and metastasis, as well as a change 
of polarization during mitosis leading to cellular 
pleomorphism.58,59 The presence of HSP 60 in the primary 
tumor indicates the refurbishment of misfolding proteins 
and affects the stability of the cytoskeleton, thus enhancing 
the progression of carcinogenesis.60
Figure 2. Pie diagram of the distribution of protein functions in the 
(a) healthy skeletal muscle, (b) primary tumor, and (c) metastatic tumor, 
according to their molecular functions as determined using PANTHER.
The metastatic tumor proteome had a profile that 
differed from the other tissues, suggesting that this 
type of tumor has a specialized molecular mechanism. 
The genetic constitution of the primary tumor and its 
metastasizing cells may be quite different.45 Stromal 
epithelial protein 1 (EPSTI1) was observed; this protein 
induces stromal fibroblasts in tumors, it is characteristic of 
invasive metastasis, and has been described as a signature 
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β-Actin is present only in non-muscle cells, and it 
has the capability to alternate from a globular (G-actin) 
to polymeric (F-actin). The G-actin isoform is converted 
into F-actin by nucleation and subsequently polymerizes 
and depolymerizes through a recycling process 
(treadmilling).61-63 Decreased levels of β-actin can be a 
consequence of cytoskeletal organization changes causing 
reduction of organization during cell division and increased 
protrusions, cell motility and chromatin remodeling.64,65
Significant levels of β-actin in metastatic tissue suggest 
a heterogeneous mechanism for formation of the primary 
tumor. Based on the metastatic tissue proteome, HSP 60 
may be associated with senescent cells output fibroblast, 
i.e., fibroblasts reached by a state in which cell division is 
limited and cannot be induced.66 Thus, active fibroblasts 
were stimulated by growth factors detected and responsible 
for distinctive features within the tissue with collagen 
presence. This explains the levels of β-actin, which is 
not typically modified in the fibroblasts.65 Therefore, this 
protein measurement may be indicative of the activation of 
response mechanisms on the development and progression 
of carcinogenesis.
Figure 3. Differences of the β-actin levels evaluated for MS/MS spectra of two specific peptides present in all tissues. The peptide 1 in healthy tissue 
exhibited an m/z 488.73, z +2, RT 14.98 min and 4.07E4 TIC; in the primary tumor it exhibited an m/z 488.74, z +2, RT 15.08 min and TIC 2.15E4; and 
on metastatic tissue it exhibited an m/z 488.72, z +2, RT 15.4 min and 3.73E4 TIC. The peptide 2 in healthy tissue had an m/z 627.95, z +3, RT 19.63 min 
and 2.66E5 TIC; in primary tumor had an m/z 627.95, z +3, RT 19.1 min and 9.48E4 TIC; and metastatic tumor had an m/z 627.93, z +3, RT 19.59 min 
and 2.58E5 TIC. Amino acids with ALC% > 90% are colored in red.
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Conclusions
We performed an in depth proteomic analysis of a high 
grade pleomorphic sarcoma of a common hippo and offered 
new opportunities of research based on the hypothesis that 
pleomorphic sarcoma tumor samples may be differentiated 
by an increase in nucleic acid binding protein class and 
for the low levels of β-actin and key cytoskeleton proteins 
as possible candidates for cell organization and dynamics 
in carcinogenesis. We also recognize that high-grade 
pleomorphic sarcomas are complex neoplasia and that 
the proteomic findings seen in this case require further 
characterization in other animals and in human tumor 
samples.
Supplementary Information
Supplementary data are available free of charge at 
http://jbcs.sbq.org.br as PDF file.
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